Press Releases

Aug 6, 2019

Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis

U.S. FDA submission for children planned for 4Q 2019
Jul 29, 2019

Sanofi delivered solid growth in Q2 2019
- Photos 4
Jul 10, 2019

FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
Jun 26, 2019

FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis

* First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)
Jun 2, 2019

Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma

News Summary: * Isatuximab, an investigational anti-CD38 monoclonal antibody, added to pomalidomide and dexamethasone prolonged progression free survival by 5 months compared to pomalidomide and dexamethasone alone (11.53 vs. 6.47 months, p=0.001, HR 0.596) * Overall response rate significantly greater with isatuximab combination therapy compared to pomalidomide and dexamethasone (60% vs. 35%, p<0.0001) * First positive randomized Phase 3 trial to evaluate an antibody in combination with pomalidomide and dexamethasone presented at this year’s ASCO annual meeting * European Medicines Agency accepted for review the Marketing Authorization Application for isatuximab

Show per page